Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure
It was developed by Metabolic Pharmaceuticals, an Australian biopharmaceutical company, in the late 1990s as a potential therapeutic for obesity and metabolic disorders
Under conditions of dysbiosis, there can be a reduction of protective bacteria with a switch to more abundant pathogenic and cancer-promoting bacteria, which can include Streptococcus bovis , Sulfidogenic bacteria, Fusobacterium nucleatum , Bacteroides fragilis , Clostridium septicum , Escherichia coli, Helicobacter pylori , Enterococcus faecalis , Human papilloma virus, John Cunnigham virus, and Epstein Barr virus
CgMYB1, an R2R3-MYB transcription factor, can alleviate abiotic stress in an annual halophyte Chenopodium glaucum
Daily administration is common in rodent studies but may not be necessary for all research objectives given Dihexa's prolonged downstream effects on synaptic density that persist well beyond plasma clearance